Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
Adherence to oral daily bisphosphonate regimens in postmenopausal osteoporosis is currently suboptimal. Less frequent dosing regimens are likely to improve patient adherence and thus, potentially, patient outcomes. A multicenter, randomized, double-blind, noninferiority study was conducted in 235 wo...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2003
|
| _version_ | 1826263638899425280 |
|---|---|
| author | Cooper, C Emkey, R McDonald, R Hawker, G Bianchi, G Wilson, K Schimmer, R |
| author_facet | Cooper, C Emkey, R McDonald, R Hawker, G Bianchi, G Wilson, K Schimmer, R |
| author_sort | Cooper, C |
| collection | OXFORD |
| description | Adherence to oral daily bisphosphonate regimens in postmenopausal osteoporosis is currently suboptimal. Less frequent dosing regimens are likely to improve patient adherence and thus, potentially, patient outcomes. A multicenter, randomized, double-blind, noninferiority study was conducted in 235 women (53-80 yr old; time since menopause >/==" BORDER="0"> 3 yr) with postmenopausal osteoporosis [lumbar spine (L1-L4) bone mineral density (BMD) T-score |
| first_indexed | 2024-03-06T19:54:59Z |
| format | Journal article |
| id | oxford-uuid:2541784d-1459-4788-921d-b207d9992511 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:54:59Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:2541784d-1459-4788-921d-b207d99925112022-03-26T11:54:41ZEfficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2541784d-1459-4788-921d-b207d9992511EnglishSymplectic Elements at Oxford2003Cooper, CEmkey, RMcDonald, RHawker, GBianchi, GWilson, KSchimmer, RAdherence to oral daily bisphosphonate regimens in postmenopausal osteoporosis is currently suboptimal. Less frequent dosing regimens are likely to improve patient adherence and thus, potentially, patient outcomes. A multicenter, randomized, double-blind, noninferiority study was conducted in 235 women (53-80 yr old; time since menopause >/==" BORDER="0"> 3 yr) with postmenopausal osteoporosis [lumbar spine (L1-L4) bone mineral density (BMD) T-score |
| spellingShingle | Cooper, C Emkey, R McDonald, R Hawker, G Bianchi, G Wilson, K Schimmer, R Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title | Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title_full | Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title_fullStr | Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title_full_unstemmed | Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title_short | Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. |
| title_sort | efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis |
| work_keys_str_mv | AT cooperc efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT emkeyr efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT mcdonaldr efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT hawkerg efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT bianchig efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT wilsonk efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis AT schimmerr efficacyandsafetyoforalweeklyibandronateinthetreatmentofpostmenopausalosteoporosis |